Phase 3 MDMA test finds a huge potential for treating a severe STSD

The multidisciplinary association for psychedelic studies (MAPS) announced the results of a phase 3 test involving MDMA assisted therapy for people with chronic and severe SSPT. The results were “highly statistically significant”, according to maps, which reports that 67% of participants who have undergone three of these MDMA assisted therapy sessions have seen enough improvement than they have no longer responded to Requirements for a diagnosis of PTSD.

The MDMA is a commonly acquired psychoactive compound as part of a drug called ecstasy. This medicine remains a substance in Annex I in the United States, which means that it has “no medical use currently accepted and a strong potential for abuse.” A growing research corpus is a challenge for this label, however, with cards causing research that may lead to a change in the way this compound is planned.

The newly announced results are the first of the Maps Phase 3 Phase 3 Therapy trial, assisted by the MDMA specifically targeting people with post-traumatic stress disorder. According to the organization, the trial has both reproduced and extended to the results of the phase 2 test, stressing that the MDMA-assisted therapy may be a quick and efficient way to treat PTSD.

The trial implied that the participant took MDMA or placebo and undergo a therapy for PTSD. While 32% of the placebo group has no longer qualified for a PTSD diagnosis after three sessions, the figure has been significantly jumped at 67% among those who received the MDMA instead of placebo.

The benefits were particularly observed in people with a subtype of SSPT involving dissociation; They have benefited more from the therapy assisted by the MDMA compared to those who have not had the dissociative subtype. The benefits can be due, in part, to put the patient in a mental state in which their fear is reduced and that their feeling of understanding and compassion is increased.

Beyond that, Phase 3 test has not seen any major tolerance or security issues with participants who have received MDMA. These participants did not experience an increase in cardiac risk, abuse potential or suicidal behavior and thoughts. However, temporary side effects have been observed, including a decrease in appetite, feel cold, nausea, sweating and muscle sealing.